Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Details 詳細情報について

• CRID

  1360580237176575104

• DOI

  10.1016/s1473-3099(19)30279-8

• ISSN

  14733099

• Web Site

  https://api.elsevier.com/content/article/PII:S1473309919302798?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1473309919302798?httpAccept=text/plain

• Data Source

  • Crossref